Scleritis Clinical Trial
Official title:
An Exploratory, Double Blind, Placebo-controlled, Randomized, Single-dose, Cross-over, Proof of Mechanism Study of Orally Administered PSI-697 in Patients With Scleritis
To evaluate the safety of an orally administered single dose of PSI-697 in subjects with scleritis, as a model of inflammatory disease. To evaluate by in vivo confocal microscopy (IVCM) the effect of a single dose of PSI-697 on leukocyte rolling in the scleral blood vessels of subjects with scleritis.
Status | Terminated |
Enrollment | 12 |
Est. completion date | April 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion: Age 18 or higher; A negative urine pregnancy test at screening for female
subjects; Female subjects must be postmenopausal or surgically sterile. Exclusion: Isolated episcleritis; Isolated posterior scleritis; Infectious scleritis. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Wyeth is now a wholly owned subsidiary of Pfizer |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate by IVCM the effect of a single dose of PSI-697 on leukocyte rolling in scleral blood vessels of subjects with scleritis. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03660618 -
LSFG-SKIN, Laser Speckle Flowgraphy
|
N/A | |
Enrolling by invitation |
NCT01613963 -
Causes of Visual Loss in Retinal Disease
|
N/A | |
Completed |
NCT03753893 -
Ocular Manifestations in Rheumatic Diseases
|
||
Completed |
NCT01835132 -
Gevokizumab for Active Scleritis
|
Phase 1/Phase 2 | |
Completed |
NCT02764697 -
Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
|
Phase 4 | |
Completed |
NCT01517074 -
Sirolimus Injections for Autoimmune Scleritis
|
Phase 1/Phase 2 | |
Completed |
NCT00415506 -
Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
|
Phase 1/Phase 2 | |
Recruiting |
NCT03465111 -
A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis
|
Phase 2 | |
Completed |
NCT00075075 -
Infliximab to Treat Non-Infectious Scleritis
|
Phase 1 | |
Recruiting |
NCT05200715 -
AutoInflammatory Disease Alliance Registry (AIDA)
|
||
Terminated |
NCT00539370 -
Human Samples and Data Repository
|
||
Active, not recruiting |
NCT03580343 -
Tofacitinib for Inflammatory Eye Disease
|
Phase 2 |